Combination of Fludarabine and Imatinib Induces Apoptosis Synergistically Through Loss of Mitochondrial Membrane Potential and Increases in Caspase-3 Enzyme Activity in Human K562 Chronic Myleloid Leukemia Cells

REFERENCES

• Ramirez, P.; DiPersio, J.F. Therapy options in imatinib failures. Oncologist 2008, 13, 424–434.
   PubMed Web of Science ®Google Scholar
• Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007, 282, 10922–10934.
   PubMed Web of Science ®Google Scholar
• Cang, S.; Liu, D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008, 1, 15.
   PubMed Web of Science ®Google Scholar
• Steinberg, M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007, 29, 2289–2308.
   PubMed Web of Science ®Google Scholar
• Sallmyr, A.; Fan, J.; Rassool, F.V. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008, 270, 1–9.
   PubMed Web of Science ®Google Scholar
• Koca, E.; Haznedaroglu, I.C. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turkish J Hematology 2005, 22(4), 161–172.
   Google Scholar
• Jakubowska, J.; Wasowska-Lukawska, M.; Czyz, M. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. Eur J Pharmacol 2008, 596, 41–49.
   PubMed Web of Science ®Google Scholar
• Henkes, M.; Van Der Kuip, H.; Aulitzky, W.E. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag 2008, 4, 163–187.
   PubMedGoogle Scholar
• Ding, X.; Herzlich, A.A.; Bishop, R.; Tuo, J.; Chan, C.C. Ocular toxicity of fludarabine: a purine analog. Expert Rev Ophthalmol 2008, 3, 97–109.
   PubMedGoogle Scholar
• Nitsche, M.; Christiansen, H.; Hermann, R.M.; Lucke, E.M.; Peters, K.; Rave-Frank, M.; Schmidberger, H.; Pradier, O. The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro. Int J Radiat Biol 2008, 84, 643–657.
   PubMed Web of Science ®Google Scholar
• Clavio, M.; Venturino, C.; Pierri, I.; Garrone, A.; Miglino, M.; Canepa, L.; Balleari, E.; Balocco, M.; Michelis, G.L.; Ballerini, F.; Gobbi, M. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004, 83, 696–703.
   PubMed Web of Science ®Google Scholar
• Harned, T.M.; Gaynon, P.S. Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag 2008, 4,327–336.
   PubMedGoogle Scholar
• Rosato, R.R.; Almenara, J.A.; Maggio, S.C.; Coe, S.; Atadja, P.; Dent, P.; Grant, S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol. Cancer Ther 2008, 7, 3285–3297.
   PubMed Web of Science ®Google Scholar
• Komarova, N.L.; Wodarz, D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci 2005, 102, 9714–9719.
   PubMed Web of Science ®Google Scholar
• Baran, Y.; Ural, A.U.; Gunduz, U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007, 12, 497–503.
   PubMed Web of Science ®Google Scholar
• Soverini, S.; Iacobucci, I.; Baccarani, M.; Martinelli, G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007, 92, 437–439.
   PubMed Web of Science ®Google Scholar
• Robak, T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007, 33, 710–728.
   PubMed Web of Science ®Google Scholar
• Cortes, J.; Jabbour, E.; Daley, G.Q.; O’Brien, S.; Verstovsek, S.; Ferrajoli, A.; Koller, C.; Zhu, Y.; Statkevich, P.; Kantarjian, H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007, 110, 1295–1302.
   PubMed Web of Science ®Google Scholar
• Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G.A.; Larson, R.A.; Cheson, B.D.; Schiffer, C.A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343, 1750–1757.
   PubMed Web of Science ®Google Scholar
• Tournilhac, O.; Cazin, B.; Leprètre, S.; Diviné, M.; Maloum, K.; Grosbois, B.; Feugier, P.; Maloisel, F.; Villard, F.; Villemagne, B.; Bastit, D.; Belhadj, K.; Azar, N.; Michallet, M.; Manhès, G.; Travade, P. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004, 103, 363– 365.
   Google Scholar
• Fruehauf, S.; Topaly, J.; Buss, E.C.; Fischer, T.; Ottmann, O.G.; Emmerich, B.; Müller, M.C.; Schuld, P.; Balleisen, L.; Hehlmann, R.; Ho, A.D.; Hochhaus, A. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007, 109, 1543–1549.
   PubMed Web of Science ®Google Scholar
• Tsimberidou, A.M.; Estey, E.; Cortes, J.E.; Garcia-Manero, G.; Faderl, S.; Verstovsek, S.; Thomas, D.A.; Ferrajoli, A.; Keating, M.J.; O’Brien, S.; Kantarjian, H.M.; Giles, F.J. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003, 52, 449–452.
   PubMed Web of Science ®Google Scholar
• Shanafelt, T.D.; Lee, Y.K.; Bone, N.D.; Strege, A.K.; Narayanan, V.L.; Sausville, E.A.; Geyer, S.M.; Kaufmann, S.H.; Kay, N.E. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 2005, 105, 2099–2106.
   PubMed Web of Science ®Google Scholar
• Moufarij, M.A.; Sampath, D.; Keating, M.J.; Plunkett, W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006, 108, 4187–4193
   PubMed Web of Science ®Google Scholar
• Korycka, A.; Robak, T. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. Leuk Lymphoma 2003, 44, 1549– 1555.
   PubMed Web of Science ®Google Scholar